ANIX sentiment intelligence

Anixa Biosciences (ANIX) CEO buys 5,000 common shares

Anixa Biosciences Inc.'s CEO and director, Amit Kumar, purchased 5,000 shares of common stock at $3.46 per share on July 20, 2026. This transaction was an open-market or private purchase, increasing his direct holdings to 640,812 shares. The purchase was not made under a Rule 10b

Tone

Positive 68/100

Event

Market update

Published

21 Jul 2026 14:41

Source

Stock Titan

Insider Buying: Titterton Lewis H Jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX)

Titterton Lewis H Jr, a Director at Anixa Biosciences Inc (ANIX), recently purchased 12,000 shares of the company, increasing his total holdings to 986,967 shares. This purchase is part of a trend of insider buying at ANIX, with 8 insider buys and no sells in the past year. Share

Tone

Positive 71/100

Event

Market update

Published

21 Jul 2026 00:40

Source

GuruFocus

Anixa Biosciences (ANIX) director purchases 12,000 shares of common stock

Anixa Biosciences director Lewis H. Titterton Jr. purchased 12,000 shares of common stock on July 20, 2026, at $3.47 per share. This transaction increases his direct holdings to 986,967 shares and was classified as an open market or private purchase. The Form 4 filing indicates a

Tone

Positive 70/100

Event

Market update

Published

20 Jul 2026 22:40

Source

Stock Titan

12 Health Care Stocks Moving In Friday's Pre-Market Session

This article lists 12 health care stocks experiencing significant movement in Friday's pre-market trading session. It provides details on both gainers like Anixa Biosciences and Barinthus Biotherapeutics, and losers such as Regenxbio and Liminatus Pharma, including their stock pe

Tone

Positive 74/100

Event

Market update

Published

17 Jul 2026 12:11

Source

Benzinga

Anixa Biosciences director buys $9,174 in common stock

Anixa Biosciences director Lewis H. Titterton Jr. purchased 2,797 shares of common stock for $9,174 on July 15, 2026, increasing his direct holdings to 974,967 shares. Despite the stock's recent gain, InvestingPro suggests the company may be overvalued. Anixa Biosciences is also

Tone

Positive 72/100

Event

Market update

Published

17 Jul 2026 02:11

Source

Investing.com

Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi

On July 15, 2026, Anixa Biosciences Inc Director Titterton Lewis H Jr purchased 2,797 shares, increasing his total holdings to 974,967 shares. This transaction reflects positive insider sentiment, as he has acquired 15,633 shares over the past year without any sales. The company

Tone

Positive 86/100

Event

Deals and strategy

Published

16 Jul 2026 15:09

Source

GuruFocus

Anixa Biosciences director buys $9,174 in common stock By Investing.com

A director at Anixa Biosciences Inc. (NASDAQ: ANIX), Lewis H. Titterton Jr., purchased 2,797 shares of common stock for $9,174. The company has recently made strides in its clinical trials and intellectual property, including a Phase 1 clinical trial for a CAR-T therapy for ovari

Tone

Positive 66/100

Event

Market update

Published

16 Jul 2026 13:09

Source

Investing.com Canada

Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stock

Anixa Biosciences Inc. director Lewis H. Titterton Jr. purchased 2,797 shares of ANIX common stock on July 15, 2026, at a price of $3.28 per share. This open-market transaction increased his direct holdings to 974,967 shares. The filing was reported on a Form 4, indicating a neut

Tone

Positive 67/100

Event

Market update

Published

16 Jul 2026 13:09

Source

Stock Titan

No Approved Vaccines Prevent Breast Cancer; Anixa Expands Coverage

Tone

Positive 66/100

Event

Market update

Published

14 Jul 2026 12:33

Source

Stock Titan

CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Recent Share Purchase

Anixa Biosciences Inc CEO, Amit Kumar, recently purchased 5,000 shares of the company, bringing his total holdings to 635,812 shares. This transaction is part of a larger trend where Kumar has acquired 31,000 shares over the past year without any sales. The acquisition, seen as a

Tone

Positive 74/100

Event

Deals and strategy

Published

13 Jul 2026 15:10

Source

GuruFocus

Form 4 Anixa Biosciences Inc For: 13 July By Investing.com

This article reports on a Form 4 filing for Anixa Biosciences Inc. on July 13. It includes the company name and filing date, and highlights that Anixa Biosciences' stock symbol is ANIX and its price performance at the time of publication was +4.25%. The content is brief and prima

Tone

Positive 59/100

Event

Market update

Published

13 Jul 2026 14:08

Source

Investing.com UK

Anixa Biosciences (ANIX) CEO Amit Kumar buys 5,000 shares at $3.04

Anixa Biosciences (ANIX) CEO Amit Kumar recently purchased 5,000 shares of common stock at $3.04 each, increasing his direct holdings to 635,812 shares. This open-market transaction, reported via a Form 4 SEC filing, represents a net buy of $15,200. The purchase signals confidenc

Tone

Positive 71/100

Event

Market update

Published

13 Jul 2026 13:10

Source

Stock Titan

Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences has announced the treatment of the first patient in the fifth cohort of its ovarian cancer CAR-T clinical trial. This trial is evaluating the company's CAR T-cell therapy targeting the folate receptor alpha, a protein commonly found on ovarian cancer cells. The

Tone

Positive 71/100

Event

Market update

Published

07 Jul 2026 06:10

Source

Moomoo

Anixa doses first patient in highest cohort of ovarian trial

Anixa Biosciences Inc. has treated the first patient in the highest dose cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer, with no dose-limiting toxicities observed to date. The therapy, liraltagene autoleucel, targets the follicle-stimu

Tone

Positive 71/100

Event

Market update

Published

06 Jul 2026 13:10

Source

Investing.com

Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level.

Anixa Biosciences reported that its CAR-T cell therapy clinical trial has shown no dose-limiting toxicities up to the 3x10⁶/kg dose level. This positive safety data is crucial for exploring higher doses and highlights the therapy's potential for patient tolerability. The company

Tone

Positive 71/100

Event

Market update

Published

06 Jul 2026 13:09

Source

Bitget

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Anixa Biosciences and Moffitt Cancer Center have advanced their ovarian cancer CAR-T clinical trial to its highest dose level yet, 1x10^7 CAR-positive cells/kg, with no dose-limiting toxicities observed to date. Five patients in the study have survived over a year, with one excee

Tone

Positive 83/100

Event

Market update

Published

06 Jul 2026 12:09

Source

PR Newswire

Anixa Biosciences secures Korean patent for breast cancer vaccine

Anixa Biosciences has secured a Korean patent for its breast cancer vaccine technology, which is exclusively licensed from Cleveland Clinic. This patent extends intellectual property protection in South Korea through 2040, addressing the increasing incidence of breast cancer in t

Tone

Positive 73/100

Event

Market update

Published

30 Jun 2026 21:10

Source

BioSpectrum Asia

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Anixa Biosciences has been granted its first Korean patent for its breast cancer vaccine technology, securing exclusive protection in South Korea through 2040. This expands Anixa's global intellectual property portfolio and strengthens its ability to pursue international developm

Tone

Positive 75/100

Event

Market update

Published

29 Jun 2026 13:09

Source

PR Newswire

Anixa Secures Patent for Breast Cancer Vaccine in South Korea

Anixa has secured a composition-of-matter patent for its breast cancer vaccine in South Korea, valid until 2040, strengthening its global intellectual property. This patent addresses the rising breast cancer incidence in South Korea and supports future commercialization, followin

Tone

Positive 71/100

Event

Market update

Published

28 Jun 2026 20:09

Source

Intellectia AI

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Anixa Biosciences announced positive data from its completed Phase 1 breast cancer vaccine trial and positive survival observations from its ongoing Phase 1 CAR-T trial for ovarian cancer. The breast cancer vaccine met all primary endpoints, demonstrating safety and immune respon

Tone

Positive 72/100

Event

Market update

Published

26 Jun 2026 20:09

Source

Sahm